Clinical Takeaway
Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome at thresholds below the traditional 50% benchmark used in clinical trials. Caregiver-reported outcomes aligned with seizure frequency data, suggesting that even modest seizure reductions can translate to real-world improvements that matter to families and patients. Clinicians should consider individualized response thresholds rather than relying solely on a fixed percentage reduction when evaluating treatment benefit in this population.
#21 Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.
Citation: Specchio Nicola et al.. Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.. CNS drugs. 2025. PMID: 40775196.
Design: 5 Journal: 0 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This post hoc analysis identifies clinically meaningful thresholds for drop seizure reduction below the conventional 50% benchmark, potentially expanding treatment response definitions for cannabidiol in Lennox-Gastaut syndrome and informing clinical decision-making in practice. By correlating seizure reduction with caregiver-reported outcomes via the CGIC scale, the study provides evidence that modest seizure improvements may deliver substantial functional and quality-of-life benefits, enabling more nuanced patient counseling and individualized treatment goals. These findings could reshape clinical expectations for anticonvulsant efficacy in a severely debilitating and pharmacoresistant condition where even partial seizure control significantly impacts patient and family outcomes.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND AND OBJECTIVE: In clinical trials of patients with Lennox-Gastaut syndrome (LGS), a ≥ 50% reduction in drop seizure frequency is generally accepted as a key endpoint. However, smaller reductions (< 50%) may yet be impactful for patients in real-world settings. This exploratory analysis evaluated the threshold for a clinically important response in drop seizures that is associated with the Caregiver Global Impression of Change (CGIC) scale score in patients with LGS treated with cannabidiol (CBD) oral solution and assessed the suitability of CGIC as an anchor for meaningful change. METHODS: This exploratory post hoc analysis included patients with LGS (N = 215, age 2-55 years) receiving CBD (Epidiolex® [USA]/Epidyolex® [EU]; 100 mg/mL oral solution) in two phase 3 randomized placebo-controlled trials (NCT02224690, April-October 2015, and NCT02224560, June- December 2015). Reduction in drop seizures (involving sudden loss of muscle tone) was anchored to CGIC scores of "slightly improved" or better or "much improved" or better, to determine the threshold at which seizure reduction can be considered clinically meaningful to patients. Spearman's correlation indicated suitability of anchors (absolute value ≥ 0.30 deemed appropriate). RESULTS: In the 215 patients receiving CBD with a CGIC score recorded, CGIC was "slightly improved" or better in 60% of patients, and "much improved" or better in 31% after 14 weeks of treatment. With a CGIC rating of "slightly improved" or better, the best threshold for a clinically important response in drop seizure reduction was – 30.6% (57.7% of patients). Mean and median percentage reductions in drop seizures were – 46.9% and – 58.6%, respectively. Using "much improved" or better, the best threshold was – 49.6% (40.5% of patients). Mean and median percentage reductions in drop seizures were – 57.6% and – 66.0%, respectively. Spearman's correlation was 0.47. CONCLUSION: Anchoring to CGIC of "slightly improved" or better, the th
🧠 This post hoc analysis of cannabidiol trials in Lennox-Gastaut syndrome usefully challenges the convention that only ≥50% seizure reduction matters clinically, suggesting that smaller improvements may correlate with meaningful caregiver-perceived benefit. The correlation between objective seizure reduction and the Caregiver Global Impression of Change scale helps contextualize outcomes in a condition where even modest seizure frequency improvements can substantially impact quality of life and safety. Important caveats include the exploratory nature of post hoc analysis, potential selection bias in which patients complete the CGIC assessment, and the need to distinguish statistical association from causation when linking seizure counts to caregiver perception. Additionally, individual patient factors such as seizure severity at baseline, comorbid conditions, and concurrent medication use may modify what constitutes a clinically meaningful response in any given case. For practitioners considering cannabidiol in refractory LGS, this work suggests that treatment response should not be dismissed solely because a patient falls short of the